Hot Features
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethy... Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.11 | 6.91823899371 | 1.59 | 2.58 | 1.53 | 1820476 | 2.13442263 | DR |
| 4 | 1.089 | 178.232405892 | 0.611 | 2.58 | 0.55 | 4415808 | 1.60251922 | DR |
| 12 | 0.8593 | 102.212442013 | 0.8407 | 2.58 | 0.55 | 1503415 | 1.56818934 | DR |
| 26 | -0.11 | -6.0773480663 | 1.81 | 2.58 | 0.55 | 1218127 | 1.53772197 | DR |
| 52 | -2.3 | -57.5 | 4 | 9.98 | 0.55 | 769635 | 2.20209445 | DR |
| 156 | -3.44 | -66.9260700389 | 5.14 | 9.98 | 0.55 | 262580 | 2.24985701 | DR |
| 260 | 1.34 | 372.222222222 | 0.36 | 13.13 | 0.36 | 159081 | 2.33065768 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.